Summary
Regeneron Pharmaceuticals, Inc. announced on March 23, 2016, the entry into a Material Definitive Agreement, specifically a License and Collaboration Agreement with Bayer HealthCare LLC. This agreement focuses on the joint development and commercialization of a new antibody targeting angiopoietin2 (ANG2), which may be used in combination with Regeneron's existing EYLEA® (aflibercept) Injection for ocular diseases. The deal structure provides Regeneron with an upfront payment and shared responsibility for development costs, while Bayer HealthCare will lead commercialization outside the United States.
Key Highlights
- 1Regeneron entered into a License and Collaboration Agreement with Bayer HealthCare LLC on March 23, 2016.
- 2The agreement covers the joint development and commercialization of an antibody to angiopoietin2 (ANG2) for ocular diseases.
- 3The ANG2 antibody may be developed in combination with Regeneron's EYLEA®.
- 4Bayer HealthCare will pay Regeneron an upfront payment of $50 million.
- 5Bayer HealthCare will commercialize the ANG2 antibody outside the United States, while Regeneron retains U.S. commercialization rights.
- 6Regeneron and Bayer HealthCare will share profits from ex-U.S. sales equally.
- 7The agreement includes a standstill provision that limits Bayer HealthCare's ability to influence Regeneron's control or acquire significant shares for a specified period.